Channel Sponsor - Coding/Billing/Collections

Sponsored by National Medical Billing Services | | (636) 273-6711

Majority of analysts rate Valeant a 'hold' — 4 things to know

A majority of stock analysts rated Laval, Canada-based Valeant Pharmaceuticals a 'hold,' the Cerbat Gem reports.

Here's what you should know.

1. Analyst opinions are split: three gave Valeant a "sell" rating, 14 rated it a 'hold' and eight gave it a "buy" rating.

2. Market analysts cut their price targets drastically. Wells Fargo slashed its target price from $19.50 to $11.50 while giving Valeant an "underperform" rating. Scotiabank dropped from the target stock price from $32 to $17 while giving it a "sector perform" rating. Morgan Stanley dropped Valeant's target from $42 to $25 while rating it as "overweight."

No analysts listed gave Valeant a target price above the previous projection.

3. Valeant opened at $18.35 on Nov. 18, 2016. Its 50-day moving average is at $20.71 and its 200-day at $24.35. Its 12-month low is $13.77 and its 12-month high is $119.87.

4. Valeant third quarter earnings were lower than analysts expected. Analysts projected a profit of $1.78 earnings per share. The company posted a $1.55 earnings per share.

More articles on coding, billing and collections:
DOJ, Anthem-Cigna attorneys make opening arguments in day 1 of antitrust trial — 5 key thoughts
ACA repeal may spur major payer withdrawal from exchanges — 6 highlights
CNN: President-elect Trump's Social Security advisor called for privatized Medicare: 3 notes 

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Top 40 Articles from the Past 6 Months